Laurus Labs extends rally, up 97% from Feb low; tops Dr Reddy's market-cap
NiveshIQ
NSE: LAURUSLABS · Healthcare
Laurus Labs Ltd.
₹1,781.30▲ ₹22.40 (+1.27%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on LAURUSLABS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Laurus Labs Ltd.
Laurus Labs Limited is a leading Indian pharmaceutical company that manufactures and sells medicines and APIs in India and internationally. The company's core business is driven by its Generics APIs and solid oral drug products for various therapeutic areas, including anti-retroviral, anti-diabetic, and cardiovascular. Laurus Labs has recently reported impressive Q1 results, with a 126% jump in profit, driven by a surge in CDMO (Contract Development and Manufacturing Organization) business and stronger margins. The company's revenue stood at ₹7270 Cr, with a net income of ₹1093 Cr. Analysts have been bullish on the stock, with Motilal Oswal setting a target price of ₹1980. The company's strong growth outlook, driven by its expanding product portfolio and increasing demand for its APIs, mak
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹5,041 Cr +72.30% | ₹5,554 Cr +10.20% | ₹6,812 Cr +22.70% |
| EBITDA Margin | 15.41% | 19.00% | 26.50% |
| Net Profit | ₹162.00 Cr -47.40% | ₹359.00 Cr +121.60% | ₹890.77 Cr +148.10% |
| EPS | ₹2.98 | ₹6.64 | ₹16.47 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Laurus Labs extends rally, up 97% from Feb low; tops Dr Reddy's market-cap
Buy Laurus Labs; target of Rs 1980: Motilal Oswal
🔒
+ 3 more stories about Laurus Labs Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹2, 026 Cr, PAT ₹362 Cr, EPS ₹6.81, EBITDA margin 31.9%. Growth context: revenue QoQ +11.9%, PAT QoQ +28.4%.
Management commentary highlights product launches, approvals, and therapy-mix improvement as key growth drivers, with su...
FY26 (last completed FY): revenue ₹6, 812 Cr, PAT ₹891 Cr, EBITDA margin 26.5%, EPS ₹16.47. Year-on-year: revenue YoY +2...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for LAURUSLABS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track LAURUSLABS alongside your other holdings
Unlock full LAURUSLABS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Laurus Labs Ltd.?
NiveshIQ detects active intelligence signals for Laurus Labs Ltd. (LAURUSLABS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Laurus Labs Ltd.?
Laurus Labs Ltd. operates in the Healthcare sector with a market capitalisation of ₹8,420,330.0L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.